About: The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID‐19
Creator	Li, Wan Wang, Shuo Gao, Ling Luo, Deng Meng, Qingtao Sun, Lifang Tesfaye, Solomon Wang, Zhongjing Xu, Zihui Yu, Ailin Ye, Yingchun
source	Medline; PMC
abstract	BACKGROUND: Although T2DM patients with COVID‐19 develop a more severe condition compared to those without diabetes, the mechanisms for this are unknown. Moreover, the impact of treatment with anti‐hyperglycemic drugs and glucocorticoids is unclear. METHODS: From 1584 COVID‐19 patients, 364 severe/critical COVID‐19 patients with clinical outcome were enrolled for the final analysis and patients without pre‐existing T2DM but elevated glucose levels were excluded. Epidemiological data were obtained and clinical‐status evaluation carried out to assess the impact of T2DM and its management on clinical outcomes. RESULTS: Of 364 enrolled severe COVID‐19 inpatients, 114 (31.3%) cases had a history of T2DM. 27(23.7%) cases died in T2DM patients, who had more severe inflammation, coagulation activation, myocardia injury, hepatic injury, and kidney injury, compared with non‐DM patients. In severe COVID‐19 patients with T2DM, we demonstrate a higher risk of all‐cause fatality with glucocorticoid treatment (Adjusted HR, 3.61; 95%CI, 1.14‐11.46; P = 0.029), and severe hyperglycemia (FPG ≥11.1 mmol/L) (Adjusted HR, 11.86; 95%CI, 1.21‐116.44; P = 0.034). CONCLUSIONS: T2DM status aggravated the clinical condition of COVID‐19 patients and increased their critical illness risk. Poor fasting blood glucose (≥ 11.1 mmol/L) and glucocorticoid treatment are associated with poor prognosis for T2DM patients with severe COVID‐19. This article is protected by copyright. All rights reserved.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1111/1753-0407.13084
bibo:pmid	32638507
has license	no-cc
sha1sum (hex)	bcdca2737912aced382c3d4ca219e6341142ac71
schema:url	https://doi.org/10.1111/1753-0407.13084
resource representing a document's title	The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID‐19
has PubMed Central identifier	PMC7361557
has PubMed identifier	32638507
schema:publication	J Diabetes
resource representing a document's body	covid:bcdca2737912aced382c3d4ca219e6341142ac71#body_text
is schema:about of	named entity 'glucocorticoids' named entity 'type 2 diabetes' named entity 'organ' named entity 'metformin' named entity 'COVID' named entity '1.06' named entity 'COVID' named entity 'COVID' named entity 'avascular necrosis' named entity 'asthma' named entity 'fatality rate' named entity 'IL-6' named entity 'Cardiovascular diseases' named entity 'metabolism' named entity 'enteritis' named entity 'CD4+' named entity 'creatinine' named entity 'FPG' named entity 'anti-hyperglycemic' named entity 'CRP' named entity 'fasting blood glucose' named entity 'emphysema' named entity 'diabetes' named entity 'anti-hyperglycemic' named entity 'chronic renal failure' named entity 'glucose' named entity 'Pulmonary diseases' named entity 'chest infection' named entity 'white blood cells' named entity '1.14' named entity 'risk factor' named entity 'Fatality rate' named entity 'heart failure' named entity 'T2DM' named entity 'glucose' named entity 'COVID' named entity 'CK-MB' named entity 'diabetes' named entity 'comorbidities' named entity 'myoglobin' named entity 'symptom' named entity 'ICU' named entity 'oxygen' named entity 'insulin' named entity 'COVID-19' named entity 'T2DM' named entity 'psychosis' named entity 'digestive diseases' named entity 'electronic medical records' named entity 'chronic obstructive pulmonary disease' named entity 'Mann-Whitney' named entity 'statistical analyses' named entity 'renal diseases' named entity 'comorbidities' named entity 'general population' named entity 'hepatic injury' named entity 'infection' named entity 'Fisher's exact test' named entity 'widely reported' named entity 'chronic bronchitis' named entity 'insulin' named entity 'COVID' named entity 'T2DM' named entity 'acarbose' named entity 'anti-hyperglycemic' named entity 'interquartile range' named entity 'medRxiv' named entity 'hyperglycaemic' named entity 'diabetes' named entity 'diabetes' named entity 'ACE2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software